- Report
- March 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- July 2021
- 120 Pages
Global
From €4502EUR$4,750USD£3,761GBP
- Report
- October 2024
- 270 Pages
China
From €3791EUR$4,000USD£3,167GBP
- Report
- February 2024
- 78 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- October 2024
- 135 Pages
China
From €1706EUR$1,800USD£1,425GBP
Cefuroxime is an antibiotic used to treat a variety of bacterial infections. It belongs to the cephalosporin class of antibiotics, which are used to treat a wide range of infections caused by bacteria. Cefuroxime is effective against a broad range of Gram-positive and Gram-negative bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli. It is also used to treat infections of the urinary tract, skin, and respiratory tract. Cefuroxime is available in both oral and injectable forms.
The cefuroxime market is highly competitive, with a number of generic and branded products available. The market is driven by the increasing prevalence of bacterial infections, the growing demand for antibiotics, and the availability of generic cefuroxime.
Some of the major companies in the cefuroxime market include Pfizer, GlaxoSmithKline, Merck, Sanofi, and Novartis. Show Less Read more